In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bioprocessing company Repligen raises $100mm in convertible notes

Executive Summary

Repligen Corp. (bioprocessing for biologic drugs) raised $100mm in 2.125% redeemable (prior to June 5, 2019) convertible senior notes due 2021. Interest is payable semi-annually in arrears (each June 1 and December 1) beginning on December 1, 2016. The conversion rate is 31.1813 shares per $1,000 principal of the notes representing a conversion price of $32.07 per share.
Deal Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies